Optimata Validates Distributed Virtual Patient Technology

Optimata, a biosimulation startup based in Ramat Gan, Israel, said last week that it is in the process of validating a distributed version of its proprietary Virtual Patient Engine technology.

The company said it is currently using the platform in a clinical trial at Nottingham City Hospital in the UK and at the Soroka Medical Center in Israel to predict breast cancer therapy outcomes for several cancer drugs, including Adriamycin, Docetaxel, Paclitaxel, Vinorelbine, and Tamoxifen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.